Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

OAKLAND, Calif.--(BUSINESS WIRE)---- $VXRT #VXRT--Gibbs Law Group continues to investigate potential legal claims on behalf of Vaxart investors.

Lost Money in Vaxart, Inc.

Novavax

Sorrento Therapeutics Inc

Major new developments in the race for a COVID-19 vaccine are driving investors to reevaluate their positions.

Why Novavax, Vaxart, Sorrento Therapeutics, and Other Coronavirus Stocks Plummeted Today

The coronavirus vaccine maker is progressing with the clinical trial process.

Why Vaxart Stock Jumped Today

San Francisco, California--(Newsfile Corp. - August 10, 2020) -  Hagens Berman urges Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Firm's Investigation of Possible Securities Fraud, Encourages Investors with $50K+ Losses and Persons Who May Assist to Contact Its Attorneys Now

If approved, the company will soon begin clinical testing of its promising, orally-administered vaccine.

Vaxart Pushes Ahead With IND Filing for COVID-19 Vaccine Candidate

New York, New York--(Newsfile Corp. - August 10, 2020) -  Levi & Korsinsky announces it has commenced an investigation of Vaxart, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vaxart, Inc. - VXRT

MILWAUKEE, Aug. 10, 2020 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating possible securities fraud claims against Vaxart (Nasdaq: VXRT) resulting from inaccurate statements Vaxart made regarding its internal controls, business practices, financial statements and prospects.

Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Vaxart, Inc.

SOUTH SAN FRANCISCO, Calif., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has been filed with the US Food and Drug Administration (FDA).

Vaxart Announces IND Filed for COVID-19 Vaccine

iBio

These two small-cap biotech stocks have intriguing COVID-19 vaccine candidates.

Better Coronavirus Stock: iBio vs. Vaxart

Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.

Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings

San Francisco, California--(Newsfile Corp. - August 3, 2020) -  Hagens Berman urges Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors Who Suffered $50K+ Losses and Persons Who May Assist Firm's Investigation of Possible Securities Fraud to Contact Its Attorneys Now

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #VXRT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Heat Biologics

Heat Biologics and Vaxart could have a lot more room to run.

2 Risky Coronavirus Vaccine Stocks That Could Make You Filthy Rich

Arcturus Therapeutics

The potential rewards are high. But so are the risks.

3 Small-Cap Coronavirus Stocks That Could Skyrocket

San Francisco, California--(Newsfile Corp. - July 31, 2020) - Hagens Berman urges Vaxart, Inc.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Vaxart (VXRT) Investors with Significant Losses and Persons Who May Assist Firm's Investigation of Possible Securities Fraud to Contact Its Attorneys Now

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #VXRT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vaxart, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces investigation of potential securities claims on behalf of shareholders of Vaxart, Inc. (NASDAQ: VXRT) resulting from allegations that Vaxart may have issued materially misleading business information to the investing public.

ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Vaxart, Inc. – VXRT

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT) complied with federal securities laws.

SHAREHOLDER ALERT: Investigation of Vaxart Announced by Holzer & Holzer, LLC

New York, New York--(Newsfile Corp. - July 28, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vaxart, Inc.

Vaxart Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vaxart, Inc. To Contact The Firm

This company has more than its COVID-19 programs going for it.

This Coronavirus Stock Just Got More Attractive: Should You Buy?

AstraZeneca

First Trust Nasdaq Pharmaceuticals ETF 

Amplify Treatments Testing & Advancements ETF

Renaissance IPO ETF

Moderna

Pfizer

VanEck Vectors Pharmaceutical ETF

Invesco DWA Healthcare Momentum ETF

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

Inovio Pharmaceuticals

Two biotechs with promising COVID-19 vaccine candidates. But one is the clear winner right now.

Better Coronavirus Stock: Inovio vs. Vaxart

PHILADELPHIA, July 27, 2020 /PRNewswire/ -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Vaxart, Inc.

Vaxart Investors With Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.

NEW YORK--(BUSINESS WIRE)-- #Investigation--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Vaxart, Inc.

VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $VXRT #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Vaxart, Inc. (VXRT) on Behalf of Investors

News for Vaxart Stock (VXRT)